Our PXA cohort appeared to be constituted only by 25% BRAF mutated patients, but this could be related to a very high quote of untested histological samples (43.7%) because of uncommon practice in past years. The gene discussed is BRAF; the disease is pleomorphic xanthoastrocytoma.